239 results about "Upper gastrointestinal" patented technology

Oral dosage forms of a bisphosphonate comprised of a safe and effective amount of a pharmaceutical composition comprising a bisphosphonate, a chelating agent, and, means for effecting delayed release of the bisphosphonate and the chelating agent in the lower gastrointestinal tract provide delivery of the pharmaceutical composition to the lower gastrointestinal tract of the mammal subject and pharmaceutically effective absorption of the bisphosphonate with or without food or beverages. The present invention substantially alleviates the interaction between bisphosphonates and food or beverages, which interaction results in the bisphosphonate active ingredient not being available for absorption. The resulting oral dosage form may thus be taken with or without food. Further, the present invention effects delivery of the bisphosphonate and the chelating agent to the lower GI tract, substantially alleviating the upper GI irritation associated with bisphosphonate therapies. These benefits simplify previously complex treatment regimens and can lead to increased patient compliance with bisphosphonate therapies.

An implantable stimulation system is provided for stimulation of the heart, phrenic nerve, gastric system, or other tissue structures accessible via a patient's upper gastrointestinal system or airway. The stimulation system includes an implantable controller housing including a pulse generator; at least one electrical lead attachable to the pulse generator; and at least one electrode carried by the electrical lead that is positionable and fixable within the upper gastrointestinal tract or airway. The controller housing may be adaptable for subcutaneous implantation, or within the upper gastrointestinal tract or airway, wherein the controller housing is proportioned to substantially permit fluid and solid flow through the upper gastrointestinal tract or airway about the controller housing. The pulse generator may be operable to deliver one or more electrical pulses effective in cardiac pacing, cardiac defibrillation, cardioversion, cardiac resynchronization therapy, diaphragm pacing, phrenic nerve stimulation, gastric electrical stimulation, or a combination thereof.

The invention pertains to cooling agents comprising N-substituted p-menthane-3-carboxamides, menthyl acetate and solubilizer, and methods for making the cooling agents. The invention also concerns pharmaceutical compositions comprising the cooling agents, including tablets, suspensions and liquid solutions having active pharmaceutical agents for treating upper gastrointestinal tract distress, and methods for treating upper gastrointestinal tract distress in humans.

The invention provides compound feed for teaching piglets to eat foods other than breast milk, which is used for weaning piglets and teaching the piglets to eat foods other than breast milk, and comprises the following components in part by weight: 212.4 parts of corn starch, 154.0 parts of bulked corn, 100.0 parts of 46 percent of bulked bean pulp, 40 parts of fish meal, 100 parts of wheat flour, 5 parts of calcium powder, 21 parts of calcium hydrophosphate, 2 parts of table salt, 20 parts of soybean oil, 5 parts of lysine, 2 parts of threonine, 1.5 parts of choline chloride, 10 parts of premix, 0.2 part of complex enzyme, 0.3 part of pig Duowei, 0.2 part of sweetener, 0.3 part of flavouring agent, 3 parts of baking soda, 20 parts of cane sugar, 30 parts of glucose, 50 parts of egg powder, 70 parts of soy protein concentrate, 50 parts of fermented bean pulp, 6 parts of acidizer, 100 parts of whey powder, 0.5 part of mould removing agent, 0.3 part of antioxidant and 0.3 part of mildewpreventive. In the invention, the problems of incomplete immune functions, low disease resistance, inadequate digestive ferment, incomplete upper gastrointestinal development, low digestion and absorption ability, susceptibility to diarrhea and the like of piglets.

Disclosed are controlled release dosage forms and related methods including: (a) a micronized or liquid base form of a drug; (b) either a pharmaceutically acceptable salt form of the drug or starting materials that are capable of reacting to form a pharmaceutically acceptable salt form of the drug; (c) an upper gastrointestinal system pharmaceutically acceptable salt form releasing structure; and (d) a colonic system base form releasing structure.

Rosiglitazone and metformin are drugs used to treat type 2 diabetes. Formulations comprising amorphous rosiglitazone and metformin are described. Other formulations include formulations for retention in the stomach and upper gastrointestinal tract. Controlled-release dosage forms in which the release of the rosiglitazone, the metformin, or both are controlled are described.

Oral dosage forms of a risedronate comprised of a safe and effective amount of a pharmaceutical composition comprising risedronate, a chelating agent, and, means for effecting delayed release of the risedronate and the chelating agent in the small intestine provide immediate release of the pharmaceutical composition to the small intestine of the mammal subject and pharmaceutically effective absorption of the bisphosphonate with or without food or beverages. The present invention substantially alleviates the interaction between risedronate and food or beverages, which interaction results in the bisphosphonate active ingredient not being available for absorption. The resulting oral dosage form may thus be taken with or without food. Further, the present invention effects delivery of risedronate and the chelating agent to the small intestine, substantially alleviating the upper GI irritation associated with bisphosphonate therapies. These benefits simplify previously complex treatment regimens and can lead to increased patient compliance with bisphosphonate therapies.

Compositions and methods for the treatment of pain in a mammal are described. More specifically, a dosage form designed for release of acetaminophen and an opioid is described, wherein the dosage form provides delivery of the drugs to the upper gastrointestinal tract (“GI”) of a mammal for an extended period of time.

An oxygen mask adaptable for upper gastrointestinal (UGI) endoscopy procedures providing enhanced oxygen concentration to maintain patient oxygenation. An oxygen mask in accordance with the present invention provides an aperture of sufficient dimensions to enable substantially unimpeded placement and manipulation of an endoscope during an endoscopic procedure while an overlying closure is in an open position and yet may also be closed to cover the aperture when the procedure is not being performed.

The present invention provides formulations of therapeutic agents that benefit from a prolonged time of controlled release in the stomach and upper gastrointestinal (GI) tract, and from an enhanced drug exposure to the upper GI tract. The formulations of the invention comprise a therapeutic agent and one or more pH sensitive polymers that are designed for accelerated hydration, expansion, disintegration and dissolution at the higher pH of the upper GI tract, thereby, ensuring that any therapeutic agent that has not been released in the stomach is released in the upper GI tract, thus maximizing absorption of therapeutic agent that has a window of absorption located at the upper GI tract.

A method for determining if blood in a stool sample originated from the upper or lower gastrointestinal tract. This includes a method for purifying and concentrating hemoglobin and its products from a stool sample to allow a simple and sensitive spectrophotometric analysis. A rapid, noninvasive determination of whether the blood originated from an upper gastrointestinal or lower gastrointestinal site is made on the basis of changes in the absorption spectra of hemoglobin that occur when hemoglobin is exposed to a highly acidic environment.

The invention discloses an integrated bile and pancreatic juice drainage pipe which comprises a water sac type bile outer drainage pipe and a pancreatic juice inner drainage pipe. The water sac type bile outer drainage pipe comprises a drainage pipe section I, a drainage pipe section II and a drainage pipe section III which are communicated in sequence. The outer wall of the drainage pipe section II is sleeved with a balloon thin film. The pancreatic juice inner drainage pipe comprises a drainage pipe body, a pipe cap and a drainage pipe tail portion. The end, far away from the drainage pipe section II, of the drainage pipe section III is matched with the drainage pipe tail portion. The integrated bile and pancreatic juice drainage pipe has strong tension force, can have the function of avoiding disengagement of the water sac type bile outer drainage pipe, is suitable for bile ducts of various diameters, has no damage to bile duct mucosa, duodenal papillae and upper gastrointestinal tract mucosa, and cannot cause obstruction of biliary tracts while avoiding displacement of the water sac type bile outer drainage pipe. The pancreatic juice inner drainage pipe is connected with the water sac type bile outer drainage pipe through a line, and the function of avoiding displacement or disengagement of the pancreatic juice inner drainage pipe is achieved.

An orally taken enteric Chinese medicine in the form of tablet, capsule, dripping pill, or soft capsule for treating unstable angina pectoris, acute myocardial infarction, cerebral haemorrhage, etc and preventing deep phlebothrombosis is prepared from leech. Its preparing process is also disclosed.

The present invention belongs to the field of medicine technology. The Carbazochrome liquid contains Carbazochrome 0.002-0.5 wt%, antioxidant 0-10 wt%, osmotic pressure regulator 0.8-75 wt%, and injection water 20-99.1 wt%. The preparation process of the Carbazochrome liquid includes dissolving osmotic pressure regulator with partial injection water in a compounding tank; adding injection level active carbon through heating and stirring for adsorption for 30 min; filtering and decarbonizing with titanium rod and adding rest injection water to obtain the solution I; dissolving Carbazochrome and antioxidant in solution I, adding injection level active carbon for adsorption for 30 min, filtering and decarbonizing with titanium rod, regulating pH value, fine filtering, detecting, packing in bottle, disinfecting and other steps. The medicine is used in intravenous transfusion for treating various hemorrhage diseases.

Disclosed is a method of manipulating the rate of upper gastrointestinal transit of a substance in a mammal. Also disclosed are methods of manipulating satiety and post-prandial visceral blood flow. A method of treating visceral pain or visceral hypersensitivity in a human subject is also described. A method for prolonging the residence time of an orally or enterally administered substance by promoting its dissolution, bioavailability and/or absorption in the small intestine is also described. These methods are related to a method of transmitting to and replicating at a second location in the central nervous system a serotonergic neural signal originating at a first location in the proximal or distal gut of a mammal and/or a method of transmitting to and replicating at a second location in the upper gastrointestinal tract a serotonergic neural signal originating at a first location in the proximal or distal gut.

Disclosed is an expandable percutaneous sheath, for introduction into the body while in a first, low cross-sectional area configuration, and subsequent expansion of at least a part of the distal end of the sheath to a second, enlarged cross-sectional configuration. The sheath is configured for use in the upper gastrointestinal tract and has utility in the performance of procedures in the esophagus and stomach. The access route is through the anterior abdominal wall to the stomach. The distal end of the sheath is maintained in the first, low cross-sectional configuration during advancement through the abdominal wall and into the stomach. The distal end of the sheath is subsequently expanded using a radial dilatation device. In an exemplary application, the sheath is utilized to provide access for a diagnostic or therapeutic procedure such as diagnosis and repair of gastro esophageal reflux disease. The sheath further can be secured within the gastrointestinal system and be used to draw the stomach wall against the abdominal wall.